New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
04:55 EDTPLX, PLX, PLX, PLX, SHPG, SHPG, SHPG, SHPG, PFE, PFE, PFE, PFE, GEVA, GEVA, GEVA, GEVA, GSK, GSK, GSK, GSK, GENZ, GENZ, GENZ, GENZ, BMRN, BMRN, BMRN, BMRN, FOLD, FOLD, FOLD, FOLD, ALIOF, ALIOF, ALIOF, ALIOFLysosomal Disease Network / Nat'l Institues of Health to co-host a symposium
9th Annual WORLD Symposium is being held in Orlando on February 12-15.
News For PLX;SHPG;PFE;GEVA;GSK;GENZ;BMRN;FOLD;ALIOF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 28, 2015
07:20 EDTPFEBrookings Institute to hold a public meeting
Subscribe for More Information
07:18 EDTPFEPfizer raises FY15 adjusted EPS view to $2.01-$2.07, consensus $2.04
Subscribe for More Information
07:17 EDTPFEPfizer reports Q2 innovative products revenue $6.63B, up 8%
Subscribe for More Information
07:02 EDTPFEPfizer reports Q2 EPS adjusted 56c, consensus 52c
Reports Q2 revenue $11.9B, consensus $11.42B.
July 27, 2015
18:30 EDTPFEAllergan CEO pursuing 'transformational deals,' FT says
In a Financial Times interview following the sale of its generics unit to Teva (TEVA), Allergan's (AGN) CEO Brent Saunders stated, "We’re going to contemplate transformational deals... We couldn’t before because of our capital structure and debt, but now we can." When asked about the timing of a potential deal, Saunders remarked, "We’re not going to plod along," and when asked about a hypothetical takeover by Pfizer (PFE), the CEO commented, "I spend zero time thinking about Pfizer and I am not doing anything to make us more or less attractive to them." Reference Link
17:31 EDTGSKRadius Health hires Dr. Lorraine Fitzpatrick as Chief Medical Officer
Radius Health (RDUS) announced that it has hired Dr. Lorraine A. Fitzpatrick as Chief Medical Officer of the Company. Dr. Fitzpatrick was previously Medicine Development Leader of an international clinical development team for Denosumab at GlaxoSmithKline (GSK), responsible for clinical development, regulatory, manufacturing, commercial, operations, epidemiology, and global health outcomes. Previously, Dr. Fitzpatrick led the clinical development of novel agents to treat musculoskeletal diseases and women's health at GlaxoSmithKline. Before joining GlaxoSmithKline, Dr. Fitzpatrick was Executive Director at Amgen, Inc. where she worked in the fields of osteoporosis and oncology.
16:00 EDTPFEOptions Update; July 27, 2015
Subscribe for More Information
15:03 EDTPFENotable companies reporting before tomorrow's open
Subscribe for More Information
12:36 EDTPFEEarnings Watch: Pfizer shares nearly flat since last earnings report
Subscribe for More Information
08:03 EDTGSKNephroGenex names Jaikrishna Patel as Chief Medical Officer
NephroGenex (NRX) announced the appointment of Dr. Jaikrishna Patel to the position of Chief Medical Officer. Dr. Patel will help guide the company’s Phase 3 PIONEER program with oral Pyridorin for the treatment of diabetic nephropathy, and the development of an intravenous formulation of Pyridorin for acute kidney injury. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline (GSK) and its predecessor companies, most recently serving as Vice President of Cardiovascular and Cardiovascular Metabolism, Global Regulatory Affairs.
July 24, 2015
05:04 EDTGSKAgenus reports GSK Malaria vaccine receives positive opinion from CHMP of EMA
Subscribe for More Information
July 23, 2015
14:01 EDTSHPGShire receives 'positive opinion' on Intuniv from CHMP
Shire announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of the once-daily, non-stimulant Intuniv, or guanfacine hydrochloride extended release, for the treatment of attention deficit/hyperactivity disorder in children and adolescents. The positive opinion is based on results from three Phase 3 pivotal studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents. The European Commission will now consider the CHMP positive opinion in its decision of whether to grant marketing authorisation for Intuniv in Europe, said Shire.
07:25 EDTSHPGShire raises FY15 EPADS growth view to mid-to-high single digit percentage
Subscribe for More Information
07:22 EDTSHPGShire reports Q2 EPS $2.63, consensus $2.81
Subscribe for More Information
July 22, 2015
08:32 EDTPFEPfizer expands lease agreement with MIT subsidiary
Subscribe for More Information
July 21, 2015
08:04 EDTPFEPfizer launches Caltrate Bone & Joint Health supplement
Pfizer Consumer Healthcare announced the launch of Caltrate Bone & Joint Health, a 3-in-1, triple action product that delivers UC-II, an exclusive form of collagen, to support healthy cartilage and promote joint flexibility, calcium and vitamin D3, to nourish strong and healthy bones, and vitamin C and minerals to support collagen production for healthy bones and skin.
07:59 EDTBMRNBioMarin gene therapy an overhang for Baxalta, says JPMorgan
Subscribe for More Information
July 20, 2015
14:32 EDTBMRNFDA panel likely to review Sarepta, BioMarin drugs in November, TheStreet says
Subscribe for More Information
11:03 EDTBMRNSarepta rises after Roth says added data can keep it ahead of BioMarin
Subscribe for More Information
08:47 EDTBMRNBioMarin reports Abrazo Phase 2 trial met threshold for tumor reduction
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use